3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
28
Neoplasm Metastasis
6
Recurrence
5
Breast Neoplasms
4
Stomach Neoplasms
3
Prostate Cancer Metastatic
3
Neoplastic Cells, Circulating
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer, Hereditary, 7
1
Penile Neoplasms
1
Nonseminomatous germ cell tumor
1
Metastatic Castration-resistant Prostate Cancer, MCRPC
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lung Neoplasms
1
Liposarcoma
1
Hormone-Resistant Prostate Cancer
1
Hormone Refractory Prostate Cancer
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Diarrhea
1
Interventions
Carboplatin
195
Cisplatin
117
Paclitaxel
107
Pemetrexed
106
Docetaxel
96
Gemcitabine
89
Radiotherapy
83
Erlotinib Hydrochloride
58
Bevacizumab
55
Etoposide
49
durvalumab
39
pembrolizumab
38
Nivolumab
31
Specimen Handling
30
Magnetic Resonance Spectroscopy
30
Irinotecan
27
Radiosurgery
26
osimertinib
24
Gefitinib
24
Drug Therapy
23
Vinorelbine
22
atezolizumab
20
Topotecan
20
Radiation
16
Cetuximab
16
Taxes
15
Surgical Procedures, Operative
14
Neoadjuvant Therapy
13
Filgrastim
13
Chemotherapy, Adjuvant
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lung Neoplasms
×
cabazitaxel
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled